Nuclear endocrinology / Doina Piciu.
By: Piciu, Doina.
Material type:
E-bookPublisher: Cham : Springer, 2017Edition: 2nd ed.Description: 1 recurso en línea (304 páginas).ISBN: 3319565826; 9783319565828.Subject: Tiroides -- Enfermedades
| Glándulas endocrinasOnline resources: Acceso a este recurso digital (usuarios Universidad Europea de Madrid)
| Item type | Current library | Collection | Call number | Status | Date due | Barcode | Item holds | |
|---|---|---|---|---|---|---|---|---|
LIBRO-E NO PRÉSTAMO
|
Madrid Digital Acceso Electrónico (UEM) | Ciencias de la Salud | RC655 .P535 2017 EB (Browse shelf(Opens below)) | Acceso electrónico | eBook.20024017 |
6.2.6.4 Technetium-99m (V) DMSA (Tc-99m (V) DMSA).
SpringerLink
Preface; Note; Contents; Contributors; Introduction; Further Reading; Part I: General Nuclear Medicine; 1: Principles of Nuclear Medicine; 1.1 Principles and History of Nuclear Medicine; 1.2 Basics of Nuclear Physics; 1.2.1 Atomic Structure; 1.2.2 Radioactivity; 1.2.2.1 Radioactive Decay: Alpha Decay (Eq. 1.1); 1.2.2.2 Radioactive Decay: Beta Decay (Eq. 1.3); 1.2.2.3 Radioactive Decay: Gamma Decay (Eq. 1.6); 1.2.2.4 Electron Capture; 1.2.2.5 Decay Equations; 1.2.3 Interaction of Radiation with Matter; 1.2.3.1 Photoelectric Effect; 1.2.3.2 Compton Effect; Further Reading.
2: Specific Measurements, Units, and TermsFurther Reading; 3: Dosimetry; 3.1 Decays of Radionuclides and Doses Calculation; 3.1.1 Fluorine F-18; 3.1.2 Gallium Ga-68 and Gallium Ga-67; 3.1.3 Radioiodine I-123; 3.1.4 Radioiodine I-124; 3.1.5 Radioiodine I-125; 3.1.6 Radioiodine I-131; 3.1.7 Indium In-111; 3.1.8 Lutetium Lu-177; 3.1.9 Techentium-99m (Tc-99m); 3.1.10 Thallium Tl-201; 3.1.11 Yttrium Y-90; 3.2 Dose Rates to Target and Critical Organ; Further Reading; 4: The Radiation Protection; 4.1 Basic Factors in Radiation Protection; 4.2 Staff Protection in Nuclear Medicine Units.
4.3 General Measures to Reduce the Irradiation of Patient4.4 Physical Factors in Radiation Protection; 4.4.1 Time; 4.4.2 Distance; 4.4.3 Shielding; 4.5 Special Recommendations for Patients Undergoing Nuclear Medicine Procedures; 4.5.1 For Female Patients of Childbearing Age and Breastfeeding; 4.5.2 Procedures in Case of Nuclear Events; 4.5.2.1 Actions for Person Decontamination; 4.5.2.2 Actions for Room Decontamination; Further Reading; 5: Equipments in Nuclear Medicine; 5.1 Gamma Camera; 5.1.1 Collimators; 5.1.2 Crystals; 5.1.3 The Photomultiplier Tubes.
5.1.4 Imaging and Processing5.2 Instruments for Thyroid Uptake Evaluation; 5.3 Positron Emission Tomography (PET) and Fusion Images Equipments (PET/CT); 5.4 Whole-Body Counting Systems; 5.5 Gamma Probe Equipment; Further Reading; 6: Radiopharmaceuticals; 6.1 Introduction; 6.2 Radiopharmaceuticals in Endocrinology; 6.2.1 Fluorine-18 Fluorodeoxyglucose (18F-FDG); 6.2.2 Fluorine-18 Fluorocholine (18F-FCH); 6.2.3 Radiopharmaceuticals with Gallium-68 and Gallium-67; 6.2.4 Radiopharmaceuticals with Radioiodine; 6.2.4.1 Radioiodine I-123 Sodium Iodide (I-123 NaI).
6.2.4.2 Radioiodine I-124 Sodium Iodide (I-124 NaI)6.2.4.3 Radioiodine I-125 Sodium Iodide (I-125 NaI); 6.2.4.4 Radioiodine I-131 Sodium Iodide (I-131 NaI); 6.2.4.5 Radioiodine I-123 Metaiodobenzylguanidine (I-123 MIBG); 6.2.4.6 Radioiodine I-131 Metaiodobenzylguanidine (I-131 MIBG); 6.2.5 Indium-111 Pentetreotide (In-111 Pentetreotide); 6.2.6 Radiopharmaceuticals with Techentium-99m; 6.2.6.1 Technetium-99m Pertechnetate (Tc-99m Pt); 6.2.6.2 Technetium-99m MIBI (Tc-99m MIBI or Sestamibi); 6.2.6.3 Technetium-99m Tetrofosmin (Tc-99m Tetrofosmin).
With endocrinologists deploying nuclear medicine on a daily basis, and with the rapid development of the latter, this concise and up-to-date guide to the vital information required has been designed to maximize relevance and ease of use in clinical practice.
There are no comments on this title.